Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Salt Lake City, UT – November 17, 2025 – PACS Group, Inc. (NYSE: PACS), a leading post-acute healthcare provider, experienced a dramatic surge in its stock price today, climbing an impressive 30%, following its announcement of a definitive plan to become current with its U.S. Securities and Exchange Commission (SEC) filings.
PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, today announced that it intends to release its third quarter 2025 financial results and file its outstanding annual and quarterly filings through September 30, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on Wednesday, November 19, 2025.
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PACS Group, Inc. (“PACS” or the “Company”) (NYSE: PACS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PACS Group, Inc. (“PACS” or the “Company”) (NYSE: PACS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), on September 10, 2025, announced that on September 9, 2025, the New York Stock Exchange (“NYSE”) Listing Operations Committee agreed to provide the Company with an additional trading period through November 19, 2025, subject to its ongoing review of the Company. The additional trading period provides PACS additional time to complete the previously announced restatement of its financial statements for the three months ended March 31, 2024, and the three and six months ended June 30, 2024 and become current with its SEC filing obligations, which are required for the Company to regain compliance with the NYSE listing standards.
U.S. stock futures are up Monday morning, but only marginally as tensions continue to flare in the Middle East, following American airstrikes on Iranian nuclear facilities over the weekend.
PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”) announced today that it will restate its previously issued condensed combined/consolidated financial statements as of and for the three months ended on March 31, 2024 included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 13, 2024 (as amended on May 21, 2024), and as of and for the three and six months ended on June 30, 2024 included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024 (collectively, the “Prior Financial Statements,” and each such quarterly period in the six months ended June 30, 2024, the “Impacted Periods”). The Prior Financial Statements and any previously furnished reports or communications of PACS describing the Company’s financial results for the Impacted Periods should no longer be relied upon.
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PACS Group, Inc. (NYSE: PACS) on behalf of long-term stockholders following a class action complaint that was filed against PACS Group on November 13, 2024 with a Class Period from April 11, 2024 to November 5, 2024. Our investigation concerns whether the board of directors of PACS Group have breached their fiduciary duties to the company.
